OR WAIT null SECS
Pearl IRB, LLC, a privately owned commercial IRB (Institutional Review Board), has announced major expansion plans. Pearl Pathways, the new parent company, will be organized into three distinct and efficient business units.
Pearl IRB remains focused on expediting the clinical research process, by offering several wrap around services including medical writing, on demand clinical research staffing, research process and regulatory training, in addition to its core IRB Board Review services. Two branches will be added to the Pearl family–Pearl ReGXP and Pearl IDEAS. Pearl ReGXP accelerates global product registrations and approvals, and supports clients’ quality compliance initiatives with a team of regulatory compliance experts. Serving startups and small service providers, Pearl IDEAS is a boutique consulting group focused on turning ideas and inventions into life science solutions.
“Our clients shaped the direction of our future growth. We listened to the needs of existing and potential clients, and developed a family of businesses to support the regulatory and product development challenges facing bio-pharma and device companies of all sizes,” shares Diana Caldwell, President and CEO of Pearl Pathways.
According to Frost & Sullivan, pharmaceutical and biotech outsourcing is growing 10% annually. “The trend to outsource device and drug development is here to stay. Our life science clients require senior professionals with a comprehensive knowledge set in the industry to guide the product development pathway. These experts need to know clinical, regulatory strategies, manufacturing, quality compliance standards, business strategies
and more. Our mix of business units allows us to provide that expertise,” states Gretchen Bowker, COO of Pearl Pathways.
Caldwell says the expansion should create 20 additional positions over the next two years.